First half results to 30th September demonstrate clear progress against the Board’s objective of creating a business with at least a £100m valuation by 2020. Proforma sales growth of 97%, driven by new customer contract wins and by pipeline progress from existing customers’ medical device programmes. The potential for operations in China (via joint venture) and the development of a new production facility for a global device manufacturer are both in late stage discussions wh
08 Dec 2015
Solid interim results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid interim results
- Published:
08 Dec 2015 -
Author:
Mark Brewer -
Pages:
10
First half results to 30th September demonstrate clear progress against the Board’s objective of creating a business with at least a £100m valuation by 2020. Proforma sales growth of 97%, driven by new customer contract wins and by pipeline progress from existing customers’ medical device programmes. The potential for operations in China (via joint venture) and the development of a new production facility for a global device manufacturer are both in late stage discussions wh